Business, energy, technology, markets and global industry news from Business News Today

trastuzumab

PharmaDeviceNews trastuzumab
Infographic showing Pfizer’s TUKYSA receiving first-line HER2-positive breast cancer maintenance approval, highlighting an 8.6-month extension in median progression-free survival.
Features & Analysis

Pfizer TUKYSA gains FDA approval for first-line HER2-positive metastatic breast cancer maintenance

Pfizer’s TUKYSA gained first-line HER2-positive breast cancer maintenance approval after extending median PFS by 8.6 months.

Read More
Representative image: ALX Oncology’s evorpacept update highlights how CD47-high biomarker data and HER2-positive metastatic breast cancer trial design could shape the next phase of oncology drug development.
Pharma & Biotech

Why ALX Oncology’s ASPEN-09 readout may matter beyond one HER2 breast cancer study

ALX Oncology has a CD47 signal. The harder test is whether ASPEN-09 can turn a tiny responder cohort into Phase 2 confidence.

Read More
Pharma & Biotech

Can Pfizer reposition TUKYSA as a first-line maintenance option after HER2CLIMB-05?

Pfizer’s tucatinib combo extends progression-free survival in HER2+ metastatic breast cancer. Find out what HER2CLIMB-05 means for frontline maintenance therapy.

Read More